Dysthymic Disorder 

  • Author: Sarah C Langenfeld, MD; Chief Editor: David Bienenfeld, MD   more...
 
Updated: Mar 8, 2012
 

Background

Dysthymic disorder is a depressive mood disorder characterized by a chronic course and an insidious onset. Many people with dysthymia describe lifelong depression. (See Presentation.)

By definition, this condition has a duration of at least 2 years (1y in adolescents and children). It is manifested as a depressed mood for most of the day, occurring more days than not, and is accompanied by at least 2 of the following symptoms (see Presentation):

  • Poor appetite or overeating
  • Insomnia or hypersomnia
  • Low energy or fatigue
  • Low self-esteem
  • Poor concentration
  • Difficulty making decisions
  • Feelings of hopelessness

To diagnose dysthymia, any major depressive episodes must not have occurred in the first 2 years of the illness (the first 1 year in children) and history of mania should not exist. The Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition, Text Revision (DSM-IV-TR)[1] allows transient euthymic episodes (periods of normal mood) of up to 2 months during the course of dysthymia.

The DSM-IV-TR categorizes dysthymia according to course specifiers. These include (1) early onset if symptoms began before age 21 years, (2) late onset if symptoms began at age 21 years or later, and (3) dysthymia with atypical features if symptoms include increased appetite or weight gain, hypersomnia, a feeling of leaden paralysis, and extreme sensitivity to rejection.

Although dysthymia was traditionally considered less severe than major depression, the consequences of dysthymia are increasingly recognized as grave; they include severe functional impairment, increased morbidity from physical disease, and increased risk of suicide. (See Prognosis.)

Anxious versus anergic dysthymia

Niculescu and Akisal proposed that dysthymia be divided into 2 subtypes: anxious dysthymia and anergic dysthymia. They described the subset of patients with anxious dysthymia as having pronounced symptoms of low self-esteem, undirected restlessness, and interpersonal rejection sensitivity. They also characterized these patients as help-seeking and more likely to make lower-lethality suicide attempts and to have a better response to selective serotonin reuptake inhibitors (SSRIs). Substances of choice for these patients include benzodiazepines, alcohol, marijuana, opiates, and possibly food. (See Treatment and Medication.)[2]

This group is compared with persons who have anergic dysthymia, characterized by low energy, hypersomnia, and anhedonia. Patients with anergic dysthymia, the authors suggest, may have a better response to treatment with agents that increase norepinephrine or dopamine. (See Treatment and Medication.)

Dysthymia versus major depression

Dysthymia should be differentiated from major depression. In contrast to dysthymia, a diagnosis of major depression requires that at least 5 or more of the following symptoms have been present most of the day, every day, for the past 2 weeks:

  • Depressed mood
  • Loss of interest or pleasure in usual activities
  • Significant weight loss or gain
  • Insomnia or hypersomnia
  • Psychomotor agitation or retardation
  • Fatigue or loss of energy
  • Feelings of worthlessness or excessive or inappropriate guilt
  • Diminished ability to think or concentrate
  • Recurrent thoughts of death or suicide

A diagnosis of major depression requires depressed mood and/or significant loss of interest or pleasure in activities. Differentiating dysthymia from major depression may be challenging in, for example, cases of major depression with a partial response to treatment.

Major depressive disorder, dysthymia, double depression, and some apparently transient dysphorias may all be manifestations of the same disease process. These varieties of depressive mood states, while distinct diagnostic entities, share similar symptoms and respond to similar pharmacologic and psychotherapeutic approaches. (See the diagram below.)[3, 4, 5, 6]

The various outcomes of dysthymia. The various outcomes of dysthymia.

Double depression

Of note, an estimated 75% of people with dysthymia meet criteria for at least 1 major depressive episode, referred to as double depression.[7] Those with dysthymia who have depressive episodes tend to have longer periods of depression and spend less time fully recovered.[8] In a 10-year follow-up study of people with dysthymia, 75% experienced some (at least 2mo) period of recovery from major depression; the mean time to recovery was 52 months from study entry. In this study, most (70%) of those who recovered experienced a relapse into another episode of depression, most commonly in the 3 years following recovery.[9]

Depressive personality disorder

The DSM IV-TR also includes research criteria for depressive personality disorder, which may also be considered in the differential diagnosis of chronic low mood. Depressive personality disorder is characterized by a depressive disposition, introversion, a tendency toward self-criticism, and pessimistic cognitive processes, with fewer of the mood and neurovegetative symptoms seen in dysthymia. Dysthymia or depression may be comorbid with depressive personality disorder.[10, 11, 12]

Next

Etiology

The cause of dysthymia, although not clear, is likely multifactorial. A biopsychosocial formulation considering the interplay of family history and other genetic factors, medical problems, psychological make-up and coping strategies, and social stressors, is helpful when considering the cause of dysthymia. Some examples of common contributing factors include the following:

  • Genetic predisposition
  • Biological factors - Such as alterations in neurotransmitters, endocrine, or inflammatory mediators
  • Chronic stress - Particularly with feelings of hopelessness and/or helplessness
  • Chronic medical illness
  • Psychosocial factors - Such as social isolation, losses
  • Ruminative coping strategies - These, as opposed to problem solving or cognitive restructuring strategies, are common among people with dysthymia and may predispose to or sustain dysthymia[13]
  • Antisocial, borderline, dependent, depressive, histrionic, or schizotypal personality traits - People diagnosed with these are at an increased risk for developing dysthymic disorder[14, 15]

Electroencephalogram (EEG) and polysomnogram data demonstrate that about 25% of people who have dysthymia have sleep changes similar to those of persons who have major depression, including shortened rapid eye movement (REM) latency, increased REM density, and poor sleep continuity.

Physiology of dysthymia

The involvement of serotonin and noradrenergic systems in dysthymia is suggested by the disease’s positive clinical responses to serotonergic and noradrenergic medications, such as SSRIs, serotonin/norepinephrine reuptake inhibitors (SNRIs), and tricyclic antidepressants.

Abnormalities in neuroendocrine systems, especially thyroid and hypothalamo-pituitary-adrenocortical (HPA) systems, have been linked to depressive disorders in general, although the HPA axis has not been adequately studied in dysthymic disorder.

Cytokines and inflammation have also been implicated in major depression; however, a link to dysthymia has not been clearly established.

Previous
Next

Epidemiology

Occurrence in the United States

Best estimates are that the lifetime risk of significant depression exceeds 25%, with a point prevalence of about 5%. The lifetime community prevalence of dysthymia is 6%. Dysthymia affects an estimated 36% of patients in outpatient mental health treatment.

Race-related demographics

Minimal research has been performed to define differences in frequency and symptoms between races. One study, the National Health and Nutrition Examination Survey III (NHANES III), found that dysthymia is more common among African Americans and Mexican Americans than among Caucasians.[16]

Sex-related demographics

For major depressive disorders, females outnumber males, with a female-to-male ratio of 2:1 during their childbearing years. Before puberty and after menopause, the 2 sexes appear to be affected about equally. In elderly people, dysthymia is relatively more frequent in females, but dysthymia adversely affects survival in males more than in females.

Age-related demographics

Most often, patients with dysthymia recall unexplained unhappiness in preadolescent childhood. Whether the DSM-IV-TR adequately addresses dysthymia in children and adolescents is a matter of some controversy.[17]

Previous
Next

Prognosis

Dysthymia is by definition chronic. Periods of depression or euthymia may occur during the course of the illness. A systematic review of epidemiologic studies found that 46-71% of persons with dysthymia reported remission at follow-up points ranging from 1-6 years.

Comorbidities, such as anxiety disorders and depressive personality disorder, are associated with lower recovery rates.[18, 10, 19, 12] Chronic stress is associated with more severe symptoms and a lower likelihood of recovery.[19]

With adequate treatment, substantial, prolonged improvement can be expected in most patients. Emphasis is increasing on the importance of striving for remission, rather than response, when treating depressive disorders.[20]

Morbidity and mortality

Patients should be closely monitored for the emergence of major depression or bipolar disorder. Review of longitudinal studies showed that 76% of dysthymic children developed major depression and that 13% developed bipolar disorder over follow-up periods of 3-12 years.

Patients with dysthymia have a higher risk of employment problems, including decreased productivity and increased unemployment.[21] A study found that at 6 months, 14% of patients with dysthymia were newly unemployed, compared with 2% new unemployment in the control group and 3% new unemployment in a group with rheumatoid arthritis.[22]

Additional concerns in dysthymia include the following:

  • Increased mortality and morbidity from unrelated physical illnesses - Dysthymia is associated with poorer self-rated health status[23]
  • Suicide, attempted or completed - Dysthymia significantly increases risk of suicide[24, 25]
Previous
Next

Patient Education

If possible, family members and other significant individuals should be helped to understand depression, to view the patient's complaints as symptoms of an illness, and to be sensitive to signs of major depression, with its risk of suicide. For example, an increase in irritability often heralds the progression from dysthymia to depression and may be apparent to people close to the patient before the patient is aware of the change.

The following Web sites contain additional patient information:

For patient education information, see the Depression Center, as well as Depression.

Previous
 
 
Contributor Information and Disclosures
Author

Sarah C Langenfeld, MD  Assistant Professor, Department of Psychiatry, University of Massachusetts Medical School; Attending Psychiatrist, Community HealthLink

Sarah C Langenfeld, MD is a member of the following medical societies: American Medical Association, American Psychiatric Association, and Massachusetts Medical Society

Disclosure: Nothing to disclose.

Coauthor(s)

Brian R Szetela, MD  Assistant Professor, Department of Psychiatry, University of Massachusetts Medical School; Consulting Psychiatrist, Psychiatric Consultation - Liaison Service, University of Massachusetts Memorial Medical Center

Brian R Szetela, MD is a member of the following medical societies: American Psychiatric Association, American Society of Addiction Medicine, and Association for Convulsive Therapy

Disclosure: Nothing to disclose.

Chief Editor

David Bienenfeld, MD  Professor of Psychiatry, Vice-Chair and Director of Residency Training, Department of Psychiatry, Wright State University, Boonshoft School of Medicine

David Bienenfeld, MD is a member of the following medical societies: American Medical Association, American Psychiatric Association, and Association for Academic Psychiatry

Disclosure: Nothing to disclose.

Additional Contributors

Rebecca S Lundquist, MD Consulting Staff, Department of Psychiatry, UMass Memorial Medical Center

Rebecca S Lundquist, MD is a member of the following medical societies: American Psychiatric Association

Disclosure: Pfizer Salary Employment; Biogen Salary Employment

Alan D Schmetzer, MD Professor Emeritus, Interim Chairman, Vice-Chair for Education, Associate Residency Training Director in General Psychiatry, Fellowship Training Director in Addiction Psychiatry, Department of Psychiatry, Indiana University School of Medicine; Addiction Psychiatrist, Midtown Mental Health Cener at Wishard Health Services

Alan D Schmetzer, MD is a member of the following medical societies: American Academy of Addiction Psychiatry, American Academy of Clinical Psychiatrists, American Academy of Psychiatry and the Law, American College of Physician Executives, American Medical Association, American Neuropsychiatric Association, American Psychiatric Association, and Association for Convulsive Therapy

Disclosure: Eli Lilly & Co. Grant/research funds Other

Francisco Talavera, PharmD, PhD Adjunct Assistant Professor, University of Nebraska Medical Center College of Pharmacy; Editor-in-Chief, Medscape Drug Reference

Disclosure: Medscape Salary Employment

References
  1. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition, Text Revision. 2000.

  2. Niculescu AB 3rd, Akiskal HS. Proposed endophenotypes of dysthymia: evolutionary, clinical and pharmacogenomic considerations. Mol Psychiatry. Jul 2001;6(4):363-6. [Medline].

  3. McCullough JP Jr, Klein DN, Borian FE, Howland RH, Riso LP, Keller MB, et al. Group comparisons of DSM-IV subtypes of chronic depression: validity of the distinctions, part 2. J Abnorm Psychol. Nov 2003;112(4):614-22. [Medline].

  4. Kessing LV. Epidemiology of Subtypes of Depression. Acta Psychiatr Scand. 2007;115 (Suppl 433):85-89.

  5. Murphy JA, Byrne GJ. Prevalence and correlates of the proposed DSM-5 diagnosis of Chronic Depressive Disorder. J Affect Disord. Feb 29 2012;[Medline].

  6. Olfson M, Liu SM, Grant BF, Blanco C. Influence of comorbid mental disorders on time to seeking treatment for major depressive disorder. Med Care. Mar 2012;50(3):227-32. [Medline]. [Full Text].

  7. Keller MB, Harrison W, Fawcett JA, Gelenberg A, Hirschfeld RM, Klein D, et al. Treatment of chronic depression with sertraline or imipramine: preliminary blinded response rates and high rates of undertreatment in the community. Psychopharmacol Bull. 1995;31(2):205-12. [Medline].

  8. Klein DN, Schwartz JE, Rose S, Leader JB. Five-year course and outcome of dysthymic disorder: A prospective, naturalistic follow-up study. Am J Psychiatry. Jun 2000;157(6):931-9. [Medline].

  9. Klein DN, Shankman SA, Rose S. Ten-year prospective follow-up study of the naturalistic course of dysthymic disorder and double depression. Am J Psychiatry. May 2006;163(5):872-80. [Medline].

  10. Laptook RS, Klein DN, Dougherty LR. Ten-year stability of depressive personality disorder in depressed outpatients. Am J Psychiatry. May 2006;163(5):865-71. [Medline].

  11. Ryder AG, Schuller DR, Bagby RM. Depressive personality and dysthymia: evaluating symptom and syndrome overlap. J Affect Disord. Apr 2006;91(2-3):217-27. [Medline].

  12. Markowitz JC, Skodol AE, Petkova E, Xie H, Cheng J, Hellerstein DJ, et al. Longitudinal comparison of depressive personality disorder and dysthymic disorder. Compr Psychiatry. Jul-Aug 2005;46(4):239-45. [Medline].

  13. Kelly O, Matheson K, Ravindran A, Merali Z, Anisman H. Ruminative coping among patients with dysthymia before and after pharmacotherapy. Depress Anxiety. 2007;24(4):233-43. [Medline].

  14. Hermens ML, van Hout HP, Terluin B, van der Windt DA, Beekman AT, et al. The prognosis of minor depression in the general population: a systematic review. Gen Hosp Psychiatry. Nov-Dec 2004;26(6):453-62. [Medline].

  15. Johnson JG, Cohen P, Kasen S, Brook JS. Personality disorder traits associated with risk for unipolar depression during middle adulthood. Psychiatry Res. Sep 15 2005;136(2-3):113-21. [Medline].

  16. Riolo SA, Nguyen TA, Greden JF, King CA. Prevalence of depression by race/ethnicity: findings from the National Health and Nutrition Examination Survey III. Am J Public Health. Jun 2005;95(6):998-1000. [Medline].

  17. Masi G, Millepiedi S, Mucci M, Pascale RR, Perugi G, Akiskal HS. Phenomenology and comorbidity of dysthymic disorder in 100 consecutively referred children and adolescents: beyond DSM-IV. Can J Psychiatry. Mar 2003;48(2):99-105. [Medline].

  18. Shankman SA, Klein DN. The impact of comorbid anxiety disorders on the course of dysthymic disorder: a 5-year prospective longitudinal study. J Affect Disord. Jul 2002;70(2):211-7. [Medline].

  19. Hayden EP, Klein DN. Outcome of dysthymic disorder at 5-year follow-up: the effect of familial psychopathology, early adversity, personality, comorbidity, and chronic stress. Am J Psychiatry. Nov 2001;158(11):1864-70. [Medline].

  20. Rush AJ, Trivedi MH, Wisniewski SR, Nierenberg AA, Stewart JW, Warden D, et al. Acute and longer-term outcomes in depressed outpatients requiring one or several treatment steps: a STAR*D report. Am J Psychiatry. Nov 2006;163(11):1905-17. [Medline].

  21. Adler DA, Irish J, McLaughlin TJ, Perissinotto C, Chang H, Hood M, et al. The work impact of dysthymia in a primary care population. Gen Hosp Psychiatry. Jul-Aug 2004;26(4):269-76. [Medline].

  22. Lerner D, Adler DA, Chang H, Lapitsky L, Hood MY, Perissinotto C. Unemployment, job retention, and productivity loss among employees with depression. Psychiatr Serv. Dec 2004;55(12):1371-8. [Medline].

  23. Barbui C, Motterlini N, Garattini L. Health status, resource consumption, and costs of dysthymia. A multi-center two-year longitudinal study. J Affect Disord. Feb 2006;90(2-3):181-6. [Medline].

  24. Bernal M, Haro JM, Bernert S, Brugha T, de Graaf R, Bruffaerts R, et al. Risk factors for suicidality in Europe: results from the ESEMED study. J Affect Disord. Aug 2007;101(1-3):27-34. [Medline].

  25. Bakken K, Vaglum P. Predictors of suicide attempters in substance-dependent patients: a six-year prospective follow-up. Clin Pract Epidemol Ment Health. 2007;3:20. [Medline].

  26. Casement MD, Shestyuk AY, Best JL, Casas BR, Glezer A, Segundo MA, et al. Anticipation of affect in dysthymia: behavioral and neurophysiological indicators. Biol Psychol. Feb 2008;77(2):197-204. [Medline].

  27. Klein DN, Shankman SA, Lewinsohn PM, Rohde P, Seeley JR. Family study of chronic depression in a community sample of young adults. Am J Psychiatry. Apr 2004;161(4):646-53. [Medline].

  28. Keitner GI, Ryan CE, Solomon DA. Realistic expectations and a disease management model for depressed patients with persistent symptoms. J Clin Psychiatry. Sep 2006;67(9):1412-21. [Medline].

  29. Airaksinen E, Larsson M, Lundberg I, Forsell Y. Cognitive functions in depressive disorders: evidence from a population-based study. Psychol Med. Jan 2004;34(1):83-91. [Medline].

  30. Leichsenring F, Hiller W, Weissberg M, Leibing E. Cognitive-behavioral therapy and psychodynamic psychotherapy: techniques, efficacy, and indications. Am J Psychother. 2006;60(3):233-59. [Medline].

  31. Leichsenring F, Leibing E. Psychodynamic psychotherapy: a systematic review of techniques, indications and empirical evidence. Psychol Psychother. Jun 2007;80:217-28. [Medline].

  32. Markowitz JC, Bleiberg KL, Christos P, Levitan E. Solving interpersonal problems correlates with symptom improvement in interpersonal psychotherapy: preliminary findings. J Nerv Ment Dis. Jan 2006;194(1):15-20. [Medline].

  33. Markowitz JC, Kocsis JH, Bleiberg KL, Christos PJ, Sacks M. A comparative trial of psychotherapy and pharmacotherapy for "pure" dysthymic patients. J Affect Disord. Dec 2005;89(1-3):167-75. [Medline].

  34. Bolton P, Bass J, Neugebauer R, Verdeli H, Clougherty KF, Wickramaratne P. Group interpersonal psychotherapy for depression in rural Uganda: a randomized controlled trial. JAMA. Jun 18 2003;289(23):3117-24. [Medline].

  35. Johnson JE, Zlotnick C. A pilot study of group interpersonal psychotherapy for depression in substance-abusing female prisoners. J Subst Abuse Treat. Jun 2008;34(4):371-7. [Medline].

  36. Comparative Effectiveness of Second-Generation Antidepressants in the Pharmacologic Treatment of Adult Depression. Accessed: May 19, 2009. AHRQ: Agency for Healthcare Research and Quality; Jan. 24, 2007. [Full Text].

  37. Carvalho AF, Cavalcante JL, Castelo MS, Lima MC. Augmentation strategies for treatment-resistant depression: a literature review. J Clin Pharm Ther. Oct 2007;32(5):415-28. [Medline].

  38. Lifschytz T, Segman R, Shalom G, Lerer B, Gur E, Golzer T, et al. Basic mechanisms of augmentation of antidepressant effects with thyroid hormone. Curr Drug Targets. Feb 2006;7(2):203-10. [Medline].

  39. Tuunainen A, Kripke DF, Endo T. Light therapy for non-seasonal depression. Cochrane Database Syst Rev. 2004;CD004050. [Medline].

  40. Hellerstein DJ, Batchelder S, Miozzo R, Kreditor D, Hyler S, Gangure D. Citalopram in the treatment of dysthymic disorder. Int Clin Psychopharmacol. May 2004;19(3):143-8. [Medline].

Previous
Next
 
The various outcomes of dysthymia.
 
 
 
All material on this website is protected by copyright, Copyright © 1994-2012 by WebMD LLC.
This website also contains material copyrighted by 3rd parties.

DISCLAIMER: The content of this Website is not influenced by sponsors. The site is designed primarily for use by qualified physicians and other medical professionals. The information contained herein should NOT be used as a substitute for the advice of an appropriately qualified and licensed physician or other health care provider. The information provided here is for educational and informational purposes only. In no way should it be considered as offering medical advice. Please check with a physician if you suspect you are ill.